This announcement is a separate document:
エーザイ：早期アルツハイマー病治療剤レカネマブ、欧州医薬品委員会（CHMP）より承認勧告を受領
Eisai: Recanemab, an early-stage treatment for Alzheimer's disease, receives approval recommendation from the European Medicines Committee (CHMP)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated